Showing 4531-4540 of 5646 results for "".
- Senate Narrowly Confirms Becerra as HHS Secretaryhttps://modernod.com/news/senate-narrowly-confirms-becerra-as-hhs-secretary/2478991/The Senate has narrowly confirmed California Attorney General Xavier Becerra as secretary of the Department of Health and Human Services, according to a FierceHealthcare
- EMA’s Blood Clot Review Exonerates AstraZeneca COVID-19 Vaccine, But Monitoring Continueshttps://modernod.com/news/emas-blood-clot-review-exonerates-astrazeneca-covid-19-vaccine-but-monitoring-continues/2478990/The European Medicines Agency (EMA) on Thursday said a review by its Pharmacovigilance Risk Assessment Committee (PRAC) has determined that AstraZeneca’s COVID-19 vaccine AZD1222 is safe and effective at preventing COVID-19, and that its benefits are “far greater” than any poten
- Moderna Gives First Vaccine Shots To Young Kids As Part Of COVID-19 Studyhttps://modernod.com/news/moderna-gives-first-vaccine-shots-to-young-kids-as-part-of-covid-19-study/2478978/Children have now received their first doses of Moderna’s COVID-19 vaccine, as the company studies the safety and effectiveness of the vaccine for kids ages 6 months to less than 12 years old, according to an NPR
- Newly Formed Ophthalmology Foundation Will Improve Global Eye Care Through Educationhttps://modernod.com/news/newly-formed-ophthalmology-foundation-will-improve-global-eye-care-through-education/2478972/The newly incorporated nonprofit Ophthalmology Foundation is laying the groundwork to improve global eye care and ophthalmic practice, particularly in low-resource and underserved countries, according to a company news release. Led by a global board of ophthalmologists, ophthalmology professors,
- EU Greenlights J&J’s Coronavirus Vaccinehttps://modernod.com/news/eu-greenlights-jjs-coronavirus-vaccine/2478966/The European Commission granted a conditional marketing authorization for Johnson & Johnson’s single-dose COVID-19 vaccine Ad26.COV2.S in people 18 years of age and over. The decision comes just hours after the European Medicines Agency (EMA) gave its backing following a review of ̶
- AAO: Looks Like the Home Office is Here to Stay. Here’s How to Protect Your Eyeshttps://modernod.com/news/aao-looks-like-the-home-office-is-here-to-stay-heres-how-to-protect-your-eyes/2478962/As home and office space merged during the pandemic, many people said they spent more time in front of screens and suffered because of it. They complained of eye strain, headaches, and dry eye, and worried that they might be doing permanent damage to their vision. Now comes a
- ASCRS Introduces Richard L. Lindstrom Lecture for 2021 Annual Meetinghttps://modernod.com/news/ascrs-introduces-richard-l-lindstrom-lecture-for-2021-annual-meeting/2478960/The American Society of Cataract and Refractive Surgery (ASCRS) has announced the inaugural Richard L. Lindstrom Lecture and Medal, which will be delivered along with other distinguished lectures at the 2021 ASCRS Annual Meeting in Las Vegas, Nevada. The Richard L. Lindstrom Lecture and Me
- New Study Links Protein Causing Alzheimer’s Disease With Common Sight Losshttps://modernod.com/news/new-study-links-protein-causing-alzheimers-disease-with-common-sight-loss/2478957/Newly published research has revealed a close link between proteins associated with Alzheimer’s disease and age-related sight loss. The findings could open the way to new treatments for patients with deteriorating vision and through this study, scientists believe they could reduce the need for us
- Samsara Vision and Medevise Consulting Announce European Partnershiphttps://modernod.com/news/samsara-vision-and-medevise-consulting-announce-european-partnership/2478956/Samsara Vision announced it will partner with Medevise Consulting to build a dedicated commercial organization to support Samsara Vision’s Tsert SI Implantable Miniature Telescope (IMT) (by Isaac Lipshitz). The two companies will collaborate to advance clinical research, coordinate reimbursement,
- Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trialhttps://modernod.com/news/graybug-vision-reports-preliminary-topline-results-from-phase-2b-altissimo-trial/2478951/Graybug Vision provided preliminary topline data from the 12-month treatment phase of its phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary microparticle depot formulation of sunitinib malate injected intravitreally. T